|
WO2021064235A1
|
|
Oligonucleotide based ex vivo cell therapy
|
|
WO2020225186A1
|
|
Pd-l1 antisense oligonucleotides for use in tumor treatment
|
|
EP3791930A1
|
|
Inhibitor of metadherin expression
|
|
WO2020011909A1
|
|
Nucleic acid polymers inhibiting the expression of xbp1
|
|
WO2019063791A1
|
|
Inhibitor inhibiting the expression of nfat5
|
|
WO2019063792A2
|
|
Oligonucleotide inhibiting the expression of chop
|
|
DE102018114467A1
|
|
Invention regarding prophylaxis and therapy against NPC-1 sensitive viruses
|
|
WO2018127599A1
|
|
Oligonucleotides inhibiting the expression of nrp1
|
|
CN110168089A
|
|
The immunosupress of CD39 expression is inhibited to restore oligonucleotides
|
|
WO2018065624A1
|
|
Immunosuppression-reverting oligonucleotides inhibiting the expression of ido
|
|
AU2017339581A1
|
|
Immunosuppression-reverting oligonucleotides inhibiting the expression of CD73
|
|
WO2018065589A1
|
|
Novel approach for treating cancer
|
|
EP3461837A1
|
|
Inhibitor inhibiting the expression of pprx1
|
|
EP3420084A1
|
|
Novel approach for treating inflammatory disorders
|
|
EP3346007A1
|
|
Immunosuppression-reverting oligonucleotides inhibiting the expression of tdo
|
|
EP3211081A1
|
|
Novel approach for treating inflammatory disorders
|
|
EP3095866A1
|
|
Agent for the prophylaxis and therapy of viral infections
|
